Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy

Suzuki, A; Kakugawa, S; Miyoshi, M; Hori, M; Suzuki, K; Furukawa, Y; Ohta, K

Suzuki, A (corresponding author), Bristol Myers Squibb KK, Shinjuku Ku, Tokyo, Japan.

LEUKEMIA, 2020; 34 (11): 3088

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索